Cell-therapy for Parkinson's disease: a systematic review and meta-analysis

Area of Science:

• Neuroscience
• Regenerative Medicine

Background:

• Parkinson's disease (PD) treatment research has long focused on cell-based strategies to replace or protect dopaminergic neurons.
• Clinical trials for PD cell-therapy have yielded mixed results, necessitating a comprehensive synthesis of findings.

Approach:

• A systematic review and meta-analysis was conducted on clinical trials investigating cell- or tissue-based therapies for PD published before July 2023.
• Eleven studies involving 210 patients, focusing on homogenous cell transplantation, were included to evaluate treatment effects using neurological scale scores.

Key Points:

• Homogenous cell-therapy demonstrated beneficial effects on disease severity and motor function in PD patients, especially levodopa responders, across various follow-up periods.
• Allogeneic cell grafts showed superior outcomes compared to autologous grafts, and transplantation was effective both within and outside the basal ganglia.
• While generally safe, some adverse events were noted, including graft-induced dyskinesia in a few cases, potentially related to surgical procedures.

Conclusions:

• This meta-analysis suggests preliminary evidence supporting the efficacy of homogenous cell-therapy for Parkinson's disease, particularly in levodopa responders.
• Allogeneic cell therapy appears more effective than autologous cell therapy, and successful transplantation is not restricted to the basal ganglia.
• Further research is warranted to optimize cell-therapy protocols and fully understand its long-term benefits and risks in PD management.